Gary D Hammer on the improvement of patient care in endocrine neoplasia-Reference-Cited by-同舟云学术

Gary D Hammer on the improvement of patient care in endocrine neoplasia

Published:2019-12-01 Issue:4 Volume:6 Page:IJE24
ISSN:2045-0869
Container-title:International Journal of Endocrine Oncology
language:en
Short-container-title:International Journal of Endocrine Oncology

Author:

Hammer Gary D¹

Affiliation:

1. Endocrine Oncology Program, Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48105, USA

Abstract

Dr Gary D Hammer is the cofounder of Millendo Therapeutics (NASDAQ, MLND, MI, USA) and the founder of Vasaragen (MI, USA), two biotechnology companies focused on rare endocrine diseases. Hammer is also an employee of the University of Michigan.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Endocrinology,Oncology,Endocrinology, Diabetes and Metabolism

Link

https://www.futuremedicine.com/doi/pdf/10.2217/ije-2019-0018

Reference7 articles.

1. University of Michigan Internal Medicine Research History (2019). www.medicine.umich.edu/dept/intmed/research/research-history

2. University of Michigan Internal Medicine Jerome W. Conn (2019). https://medicine.umich.edu/dept/intmed/divisions/metabolism-endocrinology-diabetes/about-us/jerome-w-conn-alumni-society/jerome-w-conn

3. S.717 (111th): 21st Century Cancer ALERT (Access to Life-Saving Early detection, Research and Treatment) Act (2009). www.govtrack.us/congress/bills/111/s717/text

4. The Orphan Drug Act

5. Cancer statistics, 2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Welcome to Volume 7 of the International Journal of Endocrine Oncology;International Journal of Endocrine Oncology;2020-03-01